Further studies are needed to assess whether a genetic predisposition involving PPARγ might reduce or limit the effectiveness of TZD treatments for NAFLD, as observed in mice.78 The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.